News & Media

(Tokyo, Japan and Princeton, N.J.) – Otsuka Pharmaceutical Co., Ltd. (OPCJ) and its affiliate Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) are pleased to invite investors and media to a November 4 web briefing on in-depth results from the REPRISE phase 3 trial for tolvaptan, a drug candidate for the treatment of patients in the U.S. with autosomal dominant polycystic

Tokyo, Japan and Deerfield, Ill. – Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Lundbeck announce that patient enrollment has been initiated in two global Phase 3 clinical trials to evaluate brexpiprazole for the treatment of patients with manic episodes associated with bipolar I disorder. The Phase 3 trials will evaluate the efficacy and safety of brexpiprazole in patients with bipolar

Eight data presentations supporting treatments for major depressive disorder, bipolar I disorder and schizophrenia to be presented at the upcoming annual Psych Congress (PRINCETON, N.J., & DEERFIELD, Ill.) – Otsuka Pharmaceutical Development & Commercialization, Inc. and Lundbeck U.S. today announced upcoming data presentations reinforcing the long- term safety and efficacy of

First FDA approved, once-monthly, long-acting injectable for the maintenance monotherapy treatment of bipolar I disorder in adults1,2New indication for ABILIFY MAINTENA is based on studies evaluating efficacy and safety in adult patients with bipolar I disorder1  (TOKYO, Japan & VALBY, Denmark, July 28, 2017) – Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S today announced